Disc Medicine Stock Fundamentals
| IRON Stock | 52.72 0.48 0.92% |
Disc Medicine fundamentals help investors to digest information that contributes to Disc Medicine's financial success or failures. It also enables traders to predict the movement of Disc Stock. The fundamental analysis module provides a way to measure Disc Medicine's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Disc Medicine stock.
At this time, Disc Medicine's Net Interest Income is very stable compared to the past year. As of the 25th of March 2025, Interest Income is likely to grow to about 22.4 M, while Interest Expense is likely to drop about 543.4 K.
Disc | Select Account or Indicator |
Disc Medicine Company Current Valuation Analysis
Disc Medicine's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Disc Medicine Current Valuation | 1.35 B |
Most of Disc Medicine's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Disc Medicine is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Disc Current Valuation Historical Pattern
Today, most investors in Disc Medicine Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Disc Medicine's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Disc Medicine current valuation as a starting point in their analysis.
Disc Medicine Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Disc Medicine has a Current Valuation of 1.35 B. This is 90.63% lower than that of the Biotechnology sector and 71.03% lower than that of the Health Care industry. The current valuation for all United States stocks is 91.9% higher than that of the company.
Disc Medicine Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Disc Medicine's current stock value. Our valuation model uses many indicators to compare Disc Medicine value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Disc Medicine competition to find correlations between indicators driving Disc Medicine's intrinsic value. More Info.Disc Medicine is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At this time, Disc Medicine's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Disc Medicine's earnings, one of the primary drivers of an investment's value.Disc Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Disc Medicine's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Disc Medicine could also be used in its relative valuation, which is a method of valuing Disc Medicine by comparing valuation metrics of similar companies.Disc Medicine is currently under evaluation in current valuation category among its peers.
Disc Medicine ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Disc Medicine's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Disc Medicine's managers, analysts, and investors.Environmental | Governance | Social |
Disc Fundamentals
| Return On Equity | -0.28 | ||||
| Return On Asset | -0.19 | ||||
| Current Valuation | 1.35 B | ||||
| Shares Outstanding | 34.57 M | ||||
| Shares Owned By Insiders | 11.32 % | ||||
| Shares Owned By Institutions | 79.45 % | ||||
| Number Of Shares Shorted | 2.48 M | ||||
| Price To Book | 4.07 X | ||||
| EBITDA | (129.56 M) | ||||
| Net Income | (109.36 M) | ||||
| Total Debt | 30 M | ||||
| Book Value Per Share | 14.85 X | ||||
| Cash Flow From Operations | (93.93 M) | ||||
| Short Ratio | 7.45 X | ||||
| Earnings Per Share | (3.96) X | ||||
| Target Price | 97.82 | ||||
| Number Of Employees | 84 | ||||
| Beta | 2.85 | ||||
| Market Capitalization | 1.86 B | ||||
| Total Asset | 496.77 M | ||||
| Retained Earnings | (298 M) | ||||
| Working Capital | 470.3 M | ||||
| Net Asset | 496.77 M |
About Disc Medicine Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Disc Medicine's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Disc Medicine using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Disc Medicine based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | -15.3 M | -16.1 M | |
| Cost Of Revenue | 90 K | 85.5 K |
Pair Trading with Disc Medicine
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Disc Medicine position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Disc Medicine will appreciate offsetting losses from the drop in the long position's value.Moving together with Disc Stock
Moving against Disc Stock
| 0.91 | GE | GE Aerospace | PairCorr |
| 0.87 | WM | Waste Management | PairCorr |
| 0.81 | LUCD | Lucid Diagnostics | PairCorr |
| 0.79 | PLX | Protalix Biotherapeutics | PairCorr |
| 0.36 | PG | Procter Gamble | PairCorr |
The ability to find closely correlated positions to Disc Medicine could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Disc Medicine when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Disc Medicine - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Disc Medicine to buy it.
The correlation of Disc Medicine is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Disc Medicine moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Disc Medicine moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Disc Medicine can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Disc Medicine Piotroski F Score and Disc Medicine Altman Z Score analysis. To learn how to invest in Disc Stock, please use our How to Invest in Disc Medicine guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Disc Medicine. If investors know Disc will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Disc Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Disc Medicine is measured differently than its book value, which is the value of Disc that is recorded on the company's balance sheet. Investors also form their own opinion of Disc Medicine's value that differs from its market value or its book value, called intrinsic value, which is Disc Medicine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Disc Medicine's market value can be influenced by many factors that don't directly affect Disc Medicine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Disc Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Disc Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Disc Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.